Korsana Biosciences, Inc.
KRSAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Truist Securities | maintain | Buy | Oct 20, 2021 |
| Cantor Fitzgerald | maintain | Overweight | Sep 24, 2021 |
Earnings History
Next report: Mar 29, 2027 · EPS est. $-0.86| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-3.19 | $-0.85 | — | — |
| Aug 4, 2026 | $-0.41 | $-3.45 | — | — |
| May 5, 2026 | $-2.66 | $-2.66 | $100.0K | $100.0K |
| Mar 17, 2026 | $-1.75 | $-2.66 | $1.0M | $100.0K |
| Nov 12, 2025 | $-0.30 | $-121.80 | $875.0K | $100.0K |
| Aug 5, 2025 | $-0.11 | — | $93.0K | — |
| May 6, 2025 | $-0.56 | — | $81.0K | — |
| Mar 4, 2025 | $0.22 | — | $1.8M | — |
News
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer's disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) …
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences.
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028